中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
28期
52-52,54
,共2页
南勇%毛琳琳%李苏%葛召营%赵莉
南勇%毛琳琳%李囌%葛召營%趙莉
남용%모림림%리소%갈소영%조리
Ⅲ型前列腺炎%索利那新%坦索罗辛%临床效果
Ⅲ型前列腺炎%索利那新%坦索囉辛%臨床效果
Ⅲ형전렬선염%색리나신%탄색라신%림상효과
Type III prostatitis%Solifenacin%Tamsulosin%Clinical effect
目的:探讨索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床价值。方法:2012年5月-2014年5月收治Ⅲ型前列腺炎患者94例,将其平均分为观察组(n=47)和对照组(n=47),观察组采用索利那新联合坦索罗辛治疗,对照组采用林可霉素治疗,对两组治疗效果、不良反应发生率以及治疗后心理状态评分进行观察和统计。结果:观察组患者治愈率46.81%,明显高于对照组治愈率36.17%(P<0.05);观察组不良反应发生率4.26%,明显低于对照组不良反应发生率14.89%(P<0.05);观察组SAS及SDS评分明显低于对照组相关指标(P<0.05)。结论:索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床价值显著,有效改善了患者的临床症状,值得推广。
目的:探討索利那新聯閤坦索囉辛治療Ⅲ型前列腺炎的臨床價值。方法:2012年5月-2014年5月收治Ⅲ型前列腺炎患者94例,將其平均分為觀察組(n=47)和對照組(n=47),觀察組採用索利那新聯閤坦索囉辛治療,對照組採用林可黴素治療,對兩組治療效果、不良反應髮生率以及治療後心理狀態評分進行觀察和統計。結果:觀察組患者治愈率46.81%,明顯高于對照組治愈率36.17%(P<0.05);觀察組不良反應髮生率4.26%,明顯低于對照組不良反應髮生率14.89%(P<0.05);觀察組SAS及SDS評分明顯低于對照組相關指標(P<0.05)。結論:索利那新聯閤坦索囉辛治療Ⅲ型前列腺炎的臨床價值顯著,有效改善瞭患者的臨床癥狀,值得推廣。
목적:탐토색리나신연합탄색라신치료Ⅲ형전렬선염적림상개치。방법:2012년5월-2014년5월수치Ⅲ형전렬선염환자94례,장기평균분위관찰조(n=47)화대조조(n=47),관찰조채용색리나신연합탄색라신치료,대조조채용림가매소치료,대량조치료효과、불량반응발생솔이급치료후심리상태평분진행관찰화통계。결과:관찰조환자치유솔46.81%,명현고우대조조치유솔36.17%(P<0.05);관찰조불량반응발생솔4.26%,명현저우대조조불량반응발생솔14.89%(P<0.05);관찰조SAS급SDS평분명현저우대조조상관지표(P<0.05)。결론:색리나신연합탄색라신치료Ⅲ형전렬선염적림상개치현저,유효개선료환자적림상증상,치득추엄。
Objective:To explore the clinical value of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis. Methods:94 cases with type Ⅲ prostatitis were selected from May 2012 to May 2014.They were divided into the observation group(n=47) and the control group(n=47).The observation group were treated with solifenacin combined with tamsulosin.The control group were treated with lincomycin.We compared the therapeutic effect,adverse reaction rate and mental status score after treatment of the two groups.Conclusion:In the observation group,the cure rate was 46.81%,which was significantly higher than the cure rate of 36.17% in the control group(P<0.05).In the observation group,the incidence of adverse reaction was 4.26%,which was significantly lower than that 14.89%of the control group(P<0.05).In the observation group,the SAS and the SDS score were significantly lower than those of the control group(P<0.05).Conclusion:Clinical value of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis is significant.It can effectively improve the clinical symptoms of patients,and it is worthy of promotion.